Quick search:
Content Search
Result Content Research
Result Content Research
1 Chronic GVHD Treatment Improves, But Is Still Far From Perfect
2 Study Examines Treatment Link to Transplant Complication in GVHD
3 Exploring the Implications of the ROCKstar Regimen in Chronic GVHD
4 FDA grants priority review to Orencia for acute GVHD prevention
5 Study Shows Promise of Ruxolitinib in Children With Steroid-Refractory GvHD
6 HSC Transplantation, Killer-Cell Combo May Lower Risk of GVHD in Leukemia
7 Acute Graft Versus Host Disease [GvHD] Treatment Market: Intravenous Segment to Expand at High Growth Rate
8 Post-Transplant Cyclophosphamide Appears to be a Promising Prophylactic Treatment Against GvHD in Acute Lymphoblastic Leukemia
9 FDA Grants Abatacept Priority Review to Prevent Acute GVHD
10 Posttransplant Cyclophosphamide Safety With Haploidentical Transplantation
11 Graft-Versus-Host Disease (GVHD) Market 2021 Industry Growth, Size, Share, Company Profiles and Competitive Landscape to 2028 – Stillwater Current
12 Importance of donor HLA matching confirmed, but research highlights health disparity
13 Graft Vs Host Prophylaxis With Posttransplant Cyclophosphamide Not Associated With Increased Infection Risk
14 New and Anticipated Therapies Excite the cGVHD Landscape
15 FDA Action Alert: Incyte, Verrica and Ascendis
16 Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA
17 Sanofi makes another bolt-on with Kadmon
18 Gergis Explains the Differences Between Acute and Chronic GVHD
19 Blood Irradiator Market – Owing to increasing adoption of X-ray irradiators is expected to fuel the market
20 Emerging Therapies for Acute and Chronic GVHD
21 Chao Discusses How Ruxolitinib Broadens Treatment Options in GVHD
22 Treatment for Steroid-Refractory Chronic GVHD
23 Global Graft Versus Host Disease (GVHD) Epidemiology Forecast Report 2021-2030
24 Abatacept Cuts Acute GVHD Risk in Phase 2 Study
25 VectivBio Announces Upcoming Investor Events | Your Money |
26 Immunopathology and GVHD Incidence
27 Initial Management of GVHD
28 Management of Acute GVHD
29 Kadmon's Chronic GVHD Drug Wins First FDA Approval for Company
30 AAMDS Upcoming October 2021 Events
31 Belumosudil Represents Promising Newly-Approved Option for Chronic GVHD
32 FDA Extends Review Period for Ruxolitinib in Chronic GVHD
33 FDA Grants Ruxolitinib Priority Review to Treat Chronic GVHD
34 Steroid-related complications in GVHD result in substantial costs
35 Treatment for Steroid-Refractory Acute GVHD
36 FDA grants priority review to Jakafi for chronic GVHD
37 Role of GVHD Prophylaxis
38 Looking Forward and Unmet Needs in Steroid-Refractory GVHD
39 Prevention of GVHD
40 New Approaches Seek to Meet the Challenge of Graft-Vs-Host Disease
41 FDA Extends Review Period for Belumosudil in Chronic GVHD
42 GVHD Prophylaxis
43 Newly Diagnosed Acute GVHD Shows Benefit With Itolizumab Use
44 Single-Dose Regimen Effective as Acute GVHD Prophylaxis After HSCT With Matched-Unrelated Donors
45 REACH3 Trial Yields Positive Outcomes Among Patients With GVHD Taking Ruxolitinib
46 Case 2: Steroid-Refractory Chronic GVHD
47 Durable discontinuation of immunosuppressive therapy rare in chronic GVHD
48 The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
49 Unmet Needs in GVHD
50 Management of Steroid-Refractory Acute GVHD
51 Ruxolitinib improves response rate, failure-free survival in chronic GVHD
52 Orca-T Displays GVHD Prevention, Scalability Potential, and Tolerability in Hematologic Cancers
53 TLSA: Partnership with Precision
54 Sitagliptin may prevent acute GVHD after peripheral blood stem cell transplantation
55 Ruxolitinib Improved Overall Response in the Treatment of Glucocorticoid-Refractory or -Dependent Chronic GVHD
56 REACH-2: Ruxolitinib Is Viable Option in Steroid-Refractory Acute GVHD
57 FDA Grants Belumosudil Priority Review for Chronic GVHD
58 Survival Benefit of GVHD in MDS Is Limited to Specific Patient Subgroup
59 Complications of Steroid Use in GVHD Associated With Higher Health Care Usage, Costs
60 Graft-Versus-Host Disease: Overview and More
61 Munshi Explains Staging, Prognosis, and Treatment for a Patient With Acute Graft-vs-Host-Disease
62 JAK Inhibitor Wins in Second-Line Chronic GVHD
63 Graft-Versus-Host Disease Potentially Lessened by a Single Strain of Bacteria
64 Ruxolitinib in GVHD Reveals Lower Risk of Relapse, Longer Duration of Response
65 FDA grants fast track designation to neihulizumab for acute GVHD
66 How Graft-Versus-Host Disease Is Diagnosed
67 Ruxolitinib Improves Outcomes for Certain Patients With GvHD
68 Final Thoughts: GVHD
69 Roundtable Discussion: Chen Explores Biomarkers and Staging for Acute GVHD
70 Many People with Chronic GVHD Live with Severe, Prolonged Symptoms
71 Acute vs Chronic GVHD, Incidence, and Risk Factors
72 Chao Discusses Different Staging Systems for Acute GVHD
73 Steroid-Refractory Chronic GVHD
74 How Graft-Versus-Host Disease Is Treated
75 Belumosudil: Poised to Become Necessity in Chronic GVHD
76 Research provides deeper insight into the pathogenesis of sclerodermatous chronic GVHD
77 Ruxolitinib Data Published in NEJM Underscore ORR Benefit in Chronic GVHD, Irrespective of Organs Involved at Baseline
78 Different Staging, Risk Stratification, and Treatment Methods for Acute GVHD
79 Global Graft Versus Host Disease (GVHD): Market Size from 2018 to 2030 and Overview of Treatment Practices and Emerging Drugs
80 Ruxolitinib Displays Durable Responses in Patients With Acute Graft-vs-Host Disease
81 Itolizumab Leads to Sustained Clinical Responses in Newly Diagnosed Acute GVHD
82 FDA Updates: Genentech Withdraws Tecentriq Indication; New Approvals for Xarelto, Tibsovo
83 Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation
84 Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
85 New Guidance for People with Cancer and 3rd mRNA COVID-19 Vaccination
86 Ruxolitinib Induces Prolonged Efficacy in Steroid-Refractory Acute GVHD
87 VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
88 Gergis and Rowley Examine Treatment of Moderate Chronic GVHD
89 Global Graft Versus Host Disease
90 Combining pacritinib with sirolimus-based GvHD prophylaxis may improve efficacy
91 Antibiotic Use Prior to Allogeneic Stem Cell Transplantation May Be Linked to Graft Vs Host Disease
92 What's new in combatting chronic graft-vs.-host disease
93 GVHD Prophylaxis: Similar Outcomes With PTCy and ATG
94 Case 1: GvHD Background
95 Arthritis Drug Cuts GVHD Risk in Stem Cell Transplants
96 Phase 1 Trial Demonstrates Encouraging Clinical Benefit and Promising Safety Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer Research
97 Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric
98 Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
99 FDA fast-tracks review of Incyte's Jakafi for chronic GVHD
100 Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)